STOCK TITAN

10x Genomics Inc - TXG STOCK NEWS

Welcome to our dedicated news page for 10x Genomics (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 10x Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 10x Genomics's position in the market.

Rhea-AI Summary
10x Genomics announces the use of the 10x Xenium Analyzer in a study characterizing radiation-resistance mechanisms of diffuse midline gliomas. The study provides insights into clinical response and therapeutic strategies, revealing key transcriptomic changes and cell communication pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
-
Rhea-AI Summary
10x Genomics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences earnings
-
Rhea-AI Summary
UPC denies second preliminary injunction request against NanoString Technologies, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.5%
Tags
none
Rhea-AI Summary
European Unified Patent Court issues preliminary injunction against NanoString for infringing EP 782 patent, preventing sales in 17 countries of the UPC. 10x Genomics intends to seek more than $30 million in damages for sales prior to trial in the US case. Trial for second US suit against NanoString scheduled for September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
none
-
Rhea-AI Summary
10x Genomics announces new kit to expand capabilities of its Chromium Single Cell Gene Expression Flex assay for multiomic cellular profiling
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
10x Genomics' technologies were used in a study that explains why immune checkpoint blockade is more effective for treating cancers that spread to the brain than for cancers that originate in the brain. The study analyzed resected glioblastoma and brain metastases from patients and found that brain metastases had higher T-cell infiltration into the tumor parenchyma. Researchers also identified an immune subpopulation correlated with better overall survival. The study suggests new combination immunotherapy strategies using blocking inhibitory receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12. The webcast of the chat will be available on the company's website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
10x Genomics Inc

Nasdaq:TXG

TXG Rankings

TXG Stock Data

4.12B
102.65M
2.38%
92.4%
7.15%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Pleasanton

About TXG

advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.